CYP2C19 and ischemic stroke: Similarly, Jia et al. [28] demonstrated a higher incidence of clopidogrel high on-treatment platelet reactivity among ischemic stroke CYP2C19 2* or 3* carriers compared with noncarriers (58.5% vs. 37.4%; p = 0.02), and Liu et al. [9] showed that the estimated clopidogrel resistance risk of the CYP2C19*2 allele carriers is higher than that of noncarriers (odds ratio (OR) = 2.366; p = 0.014).